NO981127L - Insulin-lignende vekstfaktor bindende protein3 (JGF_BP3) i behandling av P-53 relaterte tumorer - Google Patents
Insulin-lignende vekstfaktor bindende protein3 (JGF_BP3) i behandling av P-53 relaterte tumorerInfo
- Publication number
- NO981127L NO981127L NO981127A NO981127A NO981127L NO 981127 L NO981127 L NO 981127L NO 981127 A NO981127 A NO 981127A NO 981127 A NO981127 A NO 981127A NO 981127 L NO981127 L NO 981127L
- Authority
- NO
- Norway
- Prior art keywords
- igf
- related tumors
- treatment
- jgf
- insulin
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 title 1
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 6
- 230000001939 inductive effect Effects 0.000 abstract 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 abstract 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 abstract 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4743—Insulin-like growth factor binding protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Metoder for å behandle p53-relaterte tumorer ved tilførsel av (1) en modulator av IGF-BP3, der modulatoren oppregulerer IGF-BP3 ekspresjon eller aktivitet; (2) IGF-BP3 selv; eller (3) en ekspresjonsvektor som omfatter en nukleotidsekvens som koder for IGF-BP3. l den senere metoden kan IGF-BP3 nukleotid-sekvensene også være operativt koplet til en induserbar promoter eller enhancer, der metoden videre omfatter tilførsel av en induserende komponent som har evne til å initiere eller oppregulere ekspresjon av proteinet. Videre kan enhver av de foregående metoder inkluderes som et ytterligere trinn tilførsel av et cytotoksisk middel. Disse metoder er spesifikke eksempler på en bredere metode, behandling av p53-relaterte tumorer ved å hindre binding av IGF til IGFR.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US373095P | 1995-09-14 | 1995-09-14 | |
PCT/US1996/014623 WO1997009998A2 (en) | 1995-09-14 | 1996-09-12 | Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO981127D0 NO981127D0 (no) | 1998-03-13 |
NO981127L true NO981127L (no) | 1998-03-13 |
Family
ID=21707302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO981127A NO981127L (no) | 1995-09-14 | 1998-03-13 | Insulin-lignende vekstfaktor bindende protein3 (JGF_BP3) i behandling av P-53 relaterte tumorer |
Country Status (8)
Country | Link |
---|---|
US (1) | US5840673A (no) |
EP (1) | EP0871475A2 (no) |
JP (1) | JP2000502322A (no) |
AU (1) | AU718451B2 (no) |
CA (1) | CA2232000A1 (no) |
IL (1) | IL123383A0 (no) |
NO (1) | NO981127L (no) |
WO (1) | WO1997009998A2 (no) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6020135A (en) * | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
JP4790911B2 (ja) | 1999-01-13 | 2011-10-12 | アルケミア オンコロジー ピーティワイ リミテッド | 薬物の効力を増強するための組成物および方法 |
AU3579200A (en) * | 1999-02-26 | 2000-09-14 | Saltech I Goteborg Ab | Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1 |
AU2001264769A1 (en) * | 2000-05-17 | 2001-11-26 | Oregon Health And Sciences University | Induction of apoptosis and cell growth inhibition by protein 4.33 |
US9066919B2 (en) * | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
AUPQ879500A0 (en) * | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
AU9109001A (en) * | 2000-09-19 | 2002-04-02 | Bioexpertise Llc | Method for use of IGF-binding protein for selective sensitization of target cells in vivo |
US20050042303A1 (en) * | 2001-08-27 | 2005-02-24 | Brown Tracey Jean | Therapeutic protocols |
US6887851B2 (en) * | 2001-09-18 | 2005-05-03 | Bioexpertise, Llc | IGF-binding protein-derived peptide |
WO2003025121A2 (en) * | 2001-09-18 | 2003-03-27 | Bioexpertise, Llc | Igf-binding protein-derived peptide or small molecule |
US6914049B2 (en) * | 2001-09-18 | 2005-07-05 | Bioexpertise, Llc | IGF-binding protein-derived peptide or small molecule |
WO2003068160A2 (en) * | 2002-02-13 | 2003-08-21 | The Trustees Of Columbia University In The City Of New York | Use of insulin-like growth factor binding protein 3 (igf-bp3) for inhibition of tumor growth |
US20040005294A1 (en) * | 2002-02-25 | 2004-01-08 | Ho-Young Lee | IGFBP-3 in the diagnosis and treatment of cancer |
WO2004111262A1 (en) * | 2003-06-18 | 2004-12-23 | Pharmacia & Upjohn Company Llc | Method of identifying a selective chemotherapeutic agent |
EP1670822A2 (en) * | 2003-10-03 | 2006-06-21 | Genentech, Inc. | Igf binding proteins |
US20060084603A1 (en) * | 2004-08-06 | 2006-04-20 | Irena Kirman | IGF-BP3-related methods for inhibiting tumor growth |
US7699677B2 (en) * | 2004-12-28 | 2010-04-20 | Independent Administrative Institution, Japan Agency For Marine-Earth Science And Technology | Profiling float and usage of the profiling float |
CN103784960A (zh) * | 2005-07-27 | 2014-05-14 | 阿尔卡米亚肿瘤学股份有限公司 | 使用乙酰透明质酸的治疗方案 |
US8623354B2 (en) * | 2005-09-07 | 2014-01-07 | Alchemia Oncology Pty Limited | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2142455A1 (en) * | 1992-08-26 | 1994-03-03 | Andreas Sommer | Method for systemic treatment of catabolic conditions and systemic tissue injury |
US5573925A (en) * | 1994-11-28 | 1996-11-12 | The Wistar Institute Of Anatomy And Biology | P53 proteins with altered tetramerization domains |
-
1996
- 1996-09-12 US US08/713,052 patent/US5840673A/en not_active Expired - Lifetime
- 1996-09-12 IL IL12338396A patent/IL123383A0/xx unknown
- 1996-09-12 EP EP96930842A patent/EP0871475A2/en not_active Ceased
- 1996-09-12 CA CA002232000A patent/CA2232000A1/en not_active Abandoned
- 1996-09-12 AU AU69752/96A patent/AU718451B2/en not_active Ceased
- 1996-09-12 JP JP9512100A patent/JP2000502322A/ja active Pending
- 1996-09-12 WO PCT/US1996/014623 patent/WO1997009998A2/en not_active Application Discontinuation
-
1998
- 1998-03-13 NO NO981127A patent/NO981127L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO981127D0 (no) | 1998-03-13 |
AU718451B2 (en) | 2000-04-13 |
US5840673A (en) | 1998-11-24 |
EP0871475A2 (en) | 1998-10-21 |
WO1997009998A3 (en) | 1997-04-10 |
IL123383A0 (en) | 1998-09-24 |
JP2000502322A (ja) | 2000-02-29 |
WO1997009998A2 (en) | 1997-03-20 |
CA2232000A1 (en) | 1997-03-20 |
AU6975296A (en) | 1997-04-01 |
MX9801704A (es) | 1998-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO981127L (no) | Insulin-lignende vekstfaktor bindende protein3 (JGF_BP3) i behandling av P-53 relaterte tumorer | |
McQUILLAN et al. | Stimulation of proteoglycan biosynthesis by serum and insulin-like growth factor-I in cultured bovine articular cartilage | |
Allen et al. | Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor‐beta, insulin‐like growth factor I, and fibroblast growth factor | |
Schulz et al. | Cloning and expression of guanylin. Its existence in various mammalian tissues. | |
Heckler et al. | Generating disulfides with the Quiescin-sulfhydryl oxidases | |
AU1955388A (en) | Method for potentiating and inhibiting insulin-like growth factor activity | |
Yamaguchi et al. | Primary structure of eel (Anguilla japonica) growth hormone | |
Moise et al. | T4 gene 32 protein model for control of activity at replication fork | |
DE59712555D1 (de) | Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel | |
ATE312119T1 (de) | Glucagonähnliche peptide, zusammensetzungen und verfahren | |
WO1997022695A3 (fr) | Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer | |
CA2387870A1 (en) | Stabilized proteins | |
ATE271880T1 (de) | Methoden zur behandlung von diabetes | |
Gitay-Goren et al. | Transforming growth factor beta modulates gonadotropin receptor expression in porcine and rat granulosa cells differently | |
Burleigh Jr et al. | The isolation and primary structure of a peptide containing the oxidation-reduction active cystine of Escherichia coli lipoamide dehydrogenase | |
DE69431212D1 (de) | Behandlung von diabetes | |
HOFMANN et al. | The primary structure of α-amylase inhibitor Z-2685 from Streptomyces parvullus FH-1641. Sequence homology between inhibitor and α-amylase | |
WO1998050079A3 (en) | Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes | |
AU8811298A (en) | Novel peptides and polypeptides useful for regenerating the nervous system | |
WO1994010207A3 (en) | Truncated insulin-like growth factor binding proteins having mitogenic activity | |
Highberger et al. | Comparative studies on the amino acid sequence of the α2-CB2 peptides from chick and rat skin collagens | |
NO933742L (no) | Humant, benavledet, insulinlignende vekstfaktorbindingsprotein | |
KOTAKI | Studies on Insulin: III. On the Structure of the Alanyl Chain of Bonito Insulin | |
ATE45184T1 (de) | Vektor, teilweise oder voellig modifiziert mit dem lam b gen und mit diesem vektor modifizierte mikroorganismen befaehigt zum synthetisieren eines bestimmten externmembran-proteins, kodiert durch ein inserat ebenfalls enthalten im genannten vektor. | |
NZ332586A (en) | Suppression of endogenous gene and replacement of suppressed gene sequence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |